Arcus reports 46% confirmed ORR for casdatifan + cabozantinib in ccRCC post-immunotherapy

Arcus Biosciences, Inc.

Phase 1/1b ARC-20 interim analysis shows 46% cORR (11/24) per RECIST v1.1; median follow-up 5.3 months.
Response includes 1 complete response (4%) and 10 partial responses (42%); 50% had stable disease.
Safety evaluable population (n=42) showed acceptable safety profile with no new unexpected risks or overlapping toxicity.
Study evaluates casdatifan 100mg QD plus cabozantinib 60mg QD in patients with ccRCC who progressed on prior immunotherapy.

item 7.01item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.